MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 10-31-2025
Illumina Operating Income 2011-2025 | ILMN
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Illumina
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -833 M | -1.07 B | -123 M | 580 M | - | 985 M | 883 M | 606 M | 613 M | - | 515 M | 134 M | 201 M | 212 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 985 M | -1.07 B | 225 M |
Quarterly Operating Income Illumina
| 2025-Q3 | 2025-Q2 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 227 M | 214 M | 741 M | -1.64 B | -111 M | -88 M | -64 M | - | - | -579 M | 184 M | - | -545 M | 187 M | 193 M | - | 162 M | 96 M | 189 M | - | 308 M | 205 M | 204 M | - | 241 M | 227 M | 218 M | - | 181 M | 143 M | 52 M | - | 161 M | 162 M | 121 M | - | 141 M | 152 M | 176 M | - | 119 M | 100 M | 92.1 M | - | 45.5 M | 60 M | -45.1 M | - | 48.8 M | 43 M | 49.6 M | - | 36.8 M | 66 M | 69.4 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 741 M | -1.64 B | 60.6 M |
Operating Income of other stocks in the Diagnostics research industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Akumin
AKU
|
-28.1 M | - | -17.87 % | $ 25.9 M |  Canada |
|
Centogene N.V.
CNTG
|
-46 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Brainsway Ltd.
BWAY
|
-5 M | $ 19.33 | 0.21 % | $ 99.4 M |  Israel |
 |
Burning Rock Biotech Limited
BNR
|
-797 M | $ 20.97 | -1.38 % | $ 226 M |  China |
 |
Accelerate Diagnostics
AXDX
|
-14 M | - | -61.36 % | $ 2.46 M |  USA |
 |
Co-Diagnostics
CODX
|
-42.7 M | $ 0.23 | -4.4 % | $ 6.75 M | USA |
 |
Biocept
BIOC
|
-32 M | - | -13.05 % | $ 7.29 M | USA |
 |
Chembio Diagnostics
CEMI
|
-23.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
Castle Biosciences
CSTL
|
8.67 M | $ 39.53 | -1.4 % | $ 1.1 B | USA |
 |
BioNano Genomics
BNGO
|
-104 M | $ 1.52 | - | $ 1.93 M | USA |
 |
DarioHealth Corp.
DRIO
|
-56.2 M | $ 10.17 | 1.29 % | $ 289 M | Israel |
 |
DexCom
DXCM
|
598 M | $ 67.51 | 0.13 % | $ 26.1 B | USA |
 |
Danaher Corporation
DHR
|
4.86 B | $ 230.0 | -0.45 % | $ 168 B | USA |
 |
Exact Sciences Corporation
EXAS
|
-876 M | $ 101.56 | 0.02 % | $ 18.8 B | USA |
 |
Enzo Biochem
ENZ
|
-12.4 M | - | -8.98 % | $ 14.8 K | USA |
 |
Fulgent Genetics
FLGT
|
-73.9 M | $ 26.78 | -0.85 % | $ 810 M | USA |
 |
Global Cord Blood Corporation
CO
|
609 M | - | - | $ 399 M | China |
 |
Genetron Holdings Limited
GTH
|
-518 M | - | 0.12 % | $ 80.1 M | China |
 |
DermTech
DMTK
|
-104 M | - | -11.32 % | $ 2.94 M | USA |
 |
CareDx, Inc
CDNA
|
-203 M | $ 19.47 | -1.32 % | $ 1.05 B | USA |
 |
Celcuity
CELC
|
-113 M | $ 101.9 | -0.7 % | $ 4.02 B | USA |
 |
Anixa Biosciences
ANIX
|
-13.8 M | $ 3.21 | -6.25 % | $ 102 K | USA |
 |
Heska Corporation
HSKA
|
-20.3 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-20.8 M | - | -20.0 % | $ 1.06 M | USA |
 |
IQVIA Holdings
IQV
|
2.2 B | $ 226.52 | 0.26 % | $ 41.1 B | USA |
 |
Guardant Health
GH
|
-444 M | $ 103.35 | 0.94 % | $ 12.7 B | USA |
 |
Aspira Women's Health
AWH
|
-32.8 M | - | -6.19 % | $ 10.5 M | USA |
 |
Myriad Genetics
MYGN
|
-124 M | $ 6.44 | -1.68 % | $ 583 M | USA |
 |
Charles River Laboratories International
CRL
|
227 M | $ 203.88 | - | $ 10.5 B | USA |
 |
ENDRA Life Sciences
NDRA
|
-10.8 M | $ 4.94 | -3.14 % | $ 2.65 M | USA |
 |
Neogen Corporation
NEOG
|
-1.06 B | $ 7.12 | -0.35 % | $ 1.54 B | USA |
 |
National Research Corporation
NRC
|
40 M | $ 18.74 | 0.46 % | $ 460 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
1.35 B | $ 176.16 | 0.15 % | $ 19.6 B | USA |
|
Biodesix
BDSX
|
-34.5 M | $ 6.76 | -0.88 % | $ 877 M | USA |
 |
Motus GI Holdings
MOTS
|
-11.9 M | - | -34.28 % | $ 263 K | Israel |
 |
Laboratory Corporation of America Holdings
LH
|
1.09 B | $ 254.32 | 0.02 % | $ 21.3 B | USA |
 |
ICON Public Limited Company
ICLR
|
1.1 B | $ 182.75 | -0.51 % | $ 15.1 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
1.13 B | $ 688.22 | 0.01 % | $ 56.8 B | USA |
 |
Pacific Biosciences of California
PACB
|
-334 M | $ 1.77 | -5.85 % | $ 449 M | USA |
 |
Lantheus Holdings
LNTH
|
457 M | $ 66.73 | 0.07 % | $ 4.62 B | USA |
 |
Agilent Technologies
A
|
1.35 B | $ 138.31 | 0.03 % | $ 42 B | USA |
 |
Biomerica
BMRA
|
-5.14 M | $ 2.7 | 1.9 % | $ 6.2 M | USA |
 |
Bioventus
BVS
|
-81.7 M | $ 7.4 | 0.27 % | $ 464 M | USA |
 |
NeoGenomics
NEO
|
-92.1 M | $ 12.33 | 0.2 % | $ 1.56 B | USA |